Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

被引：0

作者：

Khan, Ali Younas ^{[1
]}

Iftikhar, Nimra ^{[1
]}

Ijaz, Awais ^{[1
]}

Tariq, Muhammad Junaid ^{[1
]}

Jamil, Faiza ^{[1
]}

Akbar, Arshia ^{[1
]}

Qureshi, Anum ^{[2
]}

Jose, Jemin Aby ^{[1
]}

Kamal, Ahmad ^{[1
]}

Abu Zar, Muhammad ^{[1
]}

Shafqat, Madeeha ^{[1
]}

Selene, Insija Ilyas ^{[1
]}

Aslam, Shehroz ^{[1
]}

Anwer, Faiz ^{[1
,3
]}

机构：

[1] Univ Arizona, Div Hematol & Oncol, Dept Med, Tucson, AZ USA

[2] Univ Arizona, Div Hematol & Oncol, Dept Med, Woodbridge, VA USA

[3] Cleveland Clin, Taussig Canc Ctr, Med Oncol, Dept Hematol, Cleveland, OH 44106 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-115867

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5484

引用

页数：4

共 50 条

[31] Setback for JAK2 inhibitors
Mark Ratner
Nature Biotechnology, 2014, 32 (2) : 119 - 119
[32] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
Vaddi, Kris
Sarlis, Nicholas J.
Gupta, Vikas
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
[33] Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib
Saha, Chandan
Harrison, Claire
EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (07) : 583 - 595
[34] Recent advances in JAK2 inhibition for the treatment of myelofibrosis
Rippel, Noa
Kremyanskaya, Marina
EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (09) : 1175 - 1186
[35] Positive new JAK2 for myelofibrosis shows promise
不详
FORMULARY, 2013, 48 (01) : 31 - 31
[36] JAK2 Inhibitors: A Reality? A Hope?
Apostolidou, Effrosyni
Kantarjian, Hagop M.
Verstovsek, Srdan
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S340 - S345
[37] JAK2 INHIBITORS: PRESENT AND FUTURE
Vainchenker, W.
Constantinescu, S.
ANNALS OF ONCOLOGY, 2013, 24 : 13 - 13
[38] Therapy with JAK 1/2 inhibitors for myelofibrosis
Romeder F.
Greil R.
Egle A.
memo - Magazine of European Medical Oncology, 2013, 6 (2) : 109 - 113
[39] Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo
Levine, Ross L.
Koppikar, Priya
Marubayashi, Sachie
Bhagwat, Neha
Taldone, Tony
Park, Christopher Y.
Chiosis, Gabriela
BLOOD, 2012, 120 (21)
[40] Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors
Vaa, Brianna E.
Tefferi, Ayalew
Gangat, Naseema
Pardanani, Animesh
Lasho, Terra L.
Finke, Christy M.
Wolanskyj, Alexandra P.
ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1185 - 1189

← 1 2 3 4 5 →